AMCP Nexus in focus: Exploring Primes GLP-1 research in depth Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s Prior to the release of Prime Therapeutics (Prime) latest cost-of-care data from its ongoing real-world research on glucagon-like peptide-1 (GLP-1) agonist drugs, Prime researchers presented findings from the Year-2 adherence and persistence study as a research poster and an education session at Academy of Managed Care Pharmacy (AMCP) Nexus 2024 in Las Vegas, Nevada
Take the First Step Toward Balance If youre dealing with fatigue, weight gain, mood fluctuations, or a sense that your hormones are normal yet something still feels off , it may be time to take a more comprehensive look
They assume they're just "getting through it" when they actually need clinical attention
It's what happens after they start taking it
(Peptide Sciences) FOXO4-DRI is built using a D-retro-inverso peptide topology (using Damino acids, reversed sequence) which makes it highly stable and resistant to proteolysis
